Published in Biochem J on September 01, 2007
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A (2009) 3.39
Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A (2008) 2.42
Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res (2008) 1.98
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A (2008) 1.86
Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem (2009) 1.65
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res (2010) 1.56
Cholesterol, the central lipid of mammalian cells. Curr Opin Cell Biol (2010) 1.54
The PCSK9 decade. J Lipid Res (2012) 1.50
Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J (2009) 1.24
Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol (2011) 1.20
In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem (2010) 1.18
Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry (2008) 1.16
Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem (2010) 1.04
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One (2012) 1.04
Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J Biol Chem (2011) 1.03
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis (2011) 1.03
Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem (2012) 1.00
Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J Biol Chem (2012) 0.99
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J (2013) 0.96
Molecular genetics of atherosclerosis. Hum Genet (2009) 0.95
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res (2009) 0.93
Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J Biol Chem (2013) 0.90
Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem (2011) 0.90
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol (2015) 0.85
Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9. J Biol Chem (2014) 0.80
PCSK9 and triglyceride-rich lipoprotein metabolism. J Biomed Res (2015) 0.79
Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats. J Transl Med (2014) 0.78
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. Nat Struct Mol Biol (2017) 0.78
Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease. Lipids Health Dis (2016) 0.77
Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor. Protein Sci (2016) 0.75
Established and emerging approaches for the management of dyslipidaemia. Scientifica (Cairo) (2012) 0.75
PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol (2017) 0.75
Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives. Acta Pharmacol Sin (2017) 0.75
Mechanism of Folding and Activation of Subtilisin Kexin Isozyme-1 (SKI-1)/Site-1 Protease (S1P). J Biol Chem (2015) 0.75
A wild-type mouse-based model for the regression of inflammation in atherosclerosis. PLoS One (2017) 0.75
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med (2006) 23.83
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet (2003) 11.67
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A (2003) 5.26
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A (2005) 4.56
NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem (2004) 4.37
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A (2004) 4.27
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem (2004) 3.93
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest (2006) 3.54
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem (2007) 3.45
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet (2006) 3.38
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A (2005) 3.15
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol (2007) 2.76
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet (2004) 2.53
Pro-sequence of subtilisin can guide the refolding of denatured subtilisin in an intermolecular process. Nature (1989) 2.33
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet (2004) 2.00
The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure (2007) 1.99
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem (2007) 1.97
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem (2007) 1.92
The alpha-lytic protease pro-region does not require a physical linkage to activate the protease domain in vivo. Nature (1989) 1.91
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet (2006) 1.89
Genetic variants in PCSK9 affect the cholesterol level in Japanese. J Hum Genet (2004) 1.55
The role of pro regions in protein folding. Curr Opin Cell Biol (1993) 1.47
The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med (Berl) (2007) 1.40
LDL-receptor structure. Calcium cages, acid baths and recycling receptors. Nature (1997) 1.32
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Structural genomics of the Thermotoga maritima proteome implemented in a high-throughput structure determination pipeline. Proc Natl Acad Sci U S A (2002) 6.00
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A (2009) 5.86
Protein production and purification. Nat Methods (2008) 3.97
Combining the polymerase incomplete primer extension method for cloning and mutagenesis with microscreening to accelerate structural genomics efforts. Proteins (2008) 3.29
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
Three-dimensional structural view of the central metabolic network of Thermotoga maritima. Science (2009) 2.33
The Polymerase Incomplete Primer Extension (PIPE) method applied to high-throughput cloning and site-directed mutagenesis. Methods Mol Biol (2009) 2.32
A general strategy for creating "inactive-conformation" abl inhibitors. Chem Biol (2006) 2.27
A dynamic mechanism for AKAP binding to RII isoforms of cAMP-dependent protein kinase. Mol Cell (2006) 2.27
XtalPred: a web server for prediction of protein crystallizability. Bioinformatics (2007) 2.26
Crystal structure of a divalent metal ion transporter CorA at 2.9 angstrom resolution. Science (2006) 2.23
Functional analysis of substrate and cofactor complex structures of a thymidylate synthase-complementing protein. Structure (2003) 2.21
An analysis of the content of food industry pledges on marketing to children. Public Health Nutr (2011) 2.10
Exposure to food advertising on television: associations with children's fast food and soft drink consumption and obesity. Econ Hum Biol (2011) 2.01
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res (2006) 1.98
Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem (2001) 1.97
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J (2010) 1.96
Influence of licensed characters on children's taste and snack preferences. Pediatrics (2010) 1.95
The site-specific incorporation of p-iodo-L-phenylalanine into proteins for structure determination. Nat Biotechnol (2004) 1.93
Shotgun crystallization strategy for structural genomics: an optimized two-tiered crystallization screen against the Thermotoga maritima proteome. Acta Crystallogr D Biol Crystallogr (2003) 1.92
The JCSG high-throughput structural biology pipeline. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 1.87
The challenge of protein structure determination--lessons from structural genomics. Protein Sci (2007) 1.82
Profiling protein function with small molecule microarrays. Proc Natl Acad Sci U S A (2002) 1.77
Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem (2005) 1.70
Rapid refinement of crystallographic protein construct definition employing enhanced hydrogen/deuterium exchange MS. Proc Natl Acad Sci U S A (2004) 1.70
An unusual mechanism of thymidylate biosynthesis in organisms containing the thyX gene. Nature (2009) 1.62
Identification of unknown protein function using metabolite cocktail screening. Structure (2012) 1.62
Completion of a Programmable DNA-Binding Small Molecule Library. Tetrahedron (2007) 1.58
In vivo incorporation of unnatural amino acids to probe structure, dynamics, and ligand binding in a large protein by nuclear magnetic resonance spectroscopy. J Am Chem Soc (2008) 1.57
Mechanistic studies of a flavin-dependent thymidylate synthase. Biochemistry (2004) 1.55
Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem (2005) 1.54
Crystal structure of TM1367 from Thermotoga maritima at 1.90 A resolution reveals an atypical member of the cyclophilin (peptidylprolyl isomerase) fold. Proteins (2006) 1.51
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. J Hypertens (2012) 1.50
Size and shape of detergent micelles determined by small-angle X-ray scattering. J Phys Chem B (2007) 1.49
Evidence for association of GABA(B) receptors with Kir3 channels and regulators of G protein signalling (RGS4) proteins. J Physiol (2006) 1.45
Crystal structure of thy1, a thymidylate synthase complementing protein from Thermotoga maritima at 2.25 A resolution. Proteins (2002) 1.45
Computational analysis of crystallization trials. Acta Crystallogr D Biol Crystallogr (2002) 1.43
An evolved aminoacyl-tRNA synthetase with atypical polysubstrate specificity. Biochemistry (2011) 1.39
The need for bold action to prevent adolescent obesity. J Adolesc Health (2009) 1.34
Food marketing expenditures aimed at youth: putting the numbers in context. Am J Prev Med (2013) 1.33
Crystal structure of the human TRPV2 channel ankyrin repeat domain. Protein Sci (2006) 1.32
Biochemical characterization of prostasin, a channel activating protease. Biochem Biophys Res Commun (2004) 1.30
Serpin1 of Arabidopsis thaliana is a suicide inhibitor for metacaspase 9. J Mol Biol (2006) 1.29
The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A (2007) 1.29
Structure of the γ-D-glutamyl-L-diamino acid endopeptidase YkfC from Bacillus cereus in complex with L-Ala-γ-D-Glu: insights into substrate recognition by NlpC/P60 cysteine peptidases. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 1.28
Expedient solid-phase synthesis of fluorogenic protease substrates using the 7-amino-4-carbamoylmethylcoumarin (ACC) fluorophore. J Org Chem (2002) 1.26
Efforts toward expansion of the genetic alphabet: structure and replication of unnatural base pairs. J Am Chem Soc (2007) 1.25
Mixing and matching detergents for membrane protein NMR structure determination. J Am Chem Soc (2009) 1.24
Structural basis of murein peptide specificity of a gamma-D-glutamyl-l-diamino acid endopeptidase. Structure (2009) 1.23
PNA-encoded protease substrate microarrays. Chem Biol (2004) 1.21
Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem J (2010) 1.20
betaL-betaM loop in the C-terminal domain of G protein-activated inwardly rectifying K(+) channels is important for G(betagamma) subunit activation. J Physiol (2004) 1.18
Screening the mammalian extracellular proteome for regulators of embryonic human stem cell pluripotency. Proc Natl Acad Sci U S A (2010) 1.17
Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J Virol (2002) 1.17
Crystal structure of a PIN (PilT N-terminus) domain (AF0591) from Archaeoglobus fulgidus at 1.90 A resolution. Proteins (2004) 1.17
Pertussis-toxin-sensitive Galpha subunits selectively bind to C-terminal domain of neuronal GIRK channels: evidence for a heterotrimeric G-protein-channel complex. Mol Cell Neurosci (2005) 1.16
Granzyme B proteolyzes receptors important to proliferation and survival, tipping the balance toward apoptosis. J Biol Chem (2006) 1.16
Crystal structure of human Pus10, a novel pseudouridine synthase. J Mol Biol (2007) 1.16
Genetic incorporation of a metal-ion chelating amino acid into proteins as a biophysical probe. J Am Chem Soc (2009) 1.16
Crystal structure of the Fic (Filamentation induced by cAMP) family protein SO4266 (gi|24375750) from Shewanella oneidensis MR-1 at 1.6 A resolution. Proteins (2009) 1.14
NMR structure determination of the hypothetical protein TM1290 from Thermotoga maritima using automated NOESY analysis. J Biomol NMR (2004) 1.13
A scaleable and integrated crystallization pipeline applied to mining the Thermotoga maritima proteome. J Struct Funct Genomics (2004) 1.13
Structural plasticity of an aminoacyl-tRNA synthetase active site. Proc Natl Acad Sci U S A (2006) 1.13
On the use of DXMS to produce more crystallizable proteins: structures of the T. maritima proteins TM0160 and TM1171. Protein Sci (2004) 1.11
Crystal structure of the type III effector AvrB from Pseudomonas syringae. Structure (2004) 1.10
Expression, purification, and characterization of Thermotoga maritima membrane proteins for structure determination. Protein Sci (2006) 1.10
Identification and structural characterization of heme binding in a novel dye-decolorizing peroxidase, TyrA. Proteins (2007) 1.09
Image-based crystal detection: a machine-learning approach. Acta Crystallogr D Biol Crystallogr (2008) 1.09
Crystal structure of a tandem cystathionine-beta-synthase (CBS) domain protein (TM0935) from Thermotoga maritima at 1.87 A resolution. Proteins (2004) 1.09
Methods and results for semi-automated cloning using integrated robotics. J Struct Funct Genomics (2005) 1.07
NMR for structural proteomics of Thermotoga maritima: screening and structure determination. J Struct Funct Genomics (2004) 1.06
Energy drinks: an emerging public health hazard for youth. J Public Health Policy (2013) 1.06
Crystal structure of the human neuropilin-1 b1 domain. Structure (2003) 1.06
Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method. J Med Chem (2006) 1.05
Crystal structures of two novel dye-decolorizing peroxidases reveal a beta-barrel fold with a conserved heme-binding motif. Proteins (2007) 1.04
Biochemical analysis of the 20 S proteasome of Trypanosoma brucei. J Biol Chem (2003) 1.04
The oligomeric structure of human granzyme A is a determinant of its extended substrate specificity. Nat Struct Biol (2003) 1.04
Crystal structure of acireductone dioxygenase (ARD) from Mus musculus at 2.06 angstrom resolution. Proteins (2006) 1.03
Shotgun crystallization strategy for structural genomics II: crystallization conditions that produce high resolution structures for T. maritima proteins. J Struct Funct Genomics (2005) 1.03
Structural analysis of papain-like NlpC/P60 superfamily enzymes with a circularly permuted topology reveals potential lipid binding sites. PLoS One (2011) 1.01
Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease. Blood (2002) 1.01
Integration of inositol phosphate signaling pathways via human ITPK1. J Biol Chem (2007) 1.01